Who Paid My Doc
A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Para
Research payments
$7,044,960
Through program year 2025, $7,044,960 in research payments was reported against A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Para, across 905 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $4,085,960 | 405 |
| 2024 | Research | $2,959,000 | 500 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Sheba Naqvi Cumming, GA Named on 58 payments
- Vivek Iyer Rochester, MN Named on 57 payments
- Bruce Prenner San Diego, CA Named on 54 payments
- Nidal Morrar Foley, AL Named on 38 payments
- Bertrand Cole Somersworth, NH Named on 33 payments
- Jose Diaz The Villages, FL Named on 28 payments
- Mary Bailey Norfolk, VA Named on 28 payments
- Alan Goldsobel San Jose, CA Named on 26 payments
- Ricardo Tan Lancaster, CA Named on 25 payments
- Lee Morrow Omaha, NE Named on 24 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.